Loading
Which cell lines, PDX, mouse models and organoid banks exist for 32 cancers and 19 targets: 222 cell lines with Cellosaurus accessions (174 in DepMap, so their dependencies and drug sensitivities are one click away), the mouse models with the paper that made them, and where to request patient-derived models.
| Identifiers | Genotype | Why it is used / alleles | Source | ||
|---|---|---|---|---|---|
| CVCL_2270, ACH-001001 | Osteosarcoma | KRAS | Highly metastatic KRAS-transformed derivative of HOS. | none | |
| CVCL_1045, ACH-000956 | Prostate cancer, Androgen receptor, PSMA | Androgen receptor, PSMA | Expresses AR-V7 splice variant; enzalutamide-resistant; moderate PSMA. | none | |
4-NQO carcinogen model 4-nitroquinoline 1-oxide in drinking water Oral dysplasia to SCC over months with tobacco-like mutations. | none | Head and neck squamous cell carcinoma | none | Oral dysplasia to SCC over months with tobacco-like mutations. | Mouse Tumor Biology database (JAX) |
4T1 Malignant neoplasms of the mouse mammary gland Mouse (BALB/c) syngeneic TNBC-like line; spontaneous lung metastasis; the standard immunotherapy model for breast. | CVCL_0125 | Triple-negative breast cancer, PD-1 | PD-1 | Mouse (BALB/c) syngeneic TNBC-like line; spontaneous lung metastasis; the standard immunotherapy model for breast. | none |
| CVCL_0126, ACH-000905 | Bladder & urothelial cancer | Nectin-4 | Basal/squamous-like, Nectin-4 high; enfortumab vedotin model. | none | |
| CVCL_VI66 | Multiple myeloma | none | Mouse (KaLwRij) myeloma; the syngeneic bone-disease model. | none | |
| CVCL_1051, ACH-000649 | Renal cell carcinoma | HIF-2α | VHL-null, HIF-2alpha dependent clear-cell line; the belzutifan model. | none | |
| CVCL_1054, ACH-001307 | Thyroid cancer, BRAF | BRAF, TP53 | Anaplastic carcinoma, BRAF V600E, TP53 R248G. | none | |
| CVCL_0132, ACH-000219 | Melanoma, BRAF | BRAF | BRAF V600E; the standard vemurafenib and dabrafenib line. | none | |
A-431 Skin squamous cell carcinoma Vulval squamous line with massive EGFR amplification; the antibody and ADC binding standard. | CVCL_0037, ACH-001328 | EGFR | EGFR | Vulval squamous line with massive EGFR amplification; the antibody and ADC binding standard. | none |
| CVCL_1056, ACH-000555 | Renal cell carcinoma | HIF-2α | VHL-null, HIF-2alpha expressing. | none | |
| CVCL_0080, ACH-000052 | Ewing sarcoma | EWSR1-FLI1 fusion, BRAF | EWSR1::FLI1 type 1, BRAF V600E (unusual), CDKN2A-null. | none | |
A549 Lung adenocarcinoma KRAS G12S, STK11-null adenocarcinoma; the default lung line for everything and therefore representative of little. | CVCL_0023, ACH-000681 | Non-small-cell lung cancer, KRAS | KRAS | KRAS G12S, STK11-null adenocarcinoma; the default lung line for everything and therefore representative of little. | none |
AB1 and AE17 Mouse asbestos-induced syngeneic lines (BALB/c and C57BL/6). | not resolved | Mesothelioma | PD-1 | Mouse asbestos-induced syngeneic lines (BALB/c and C57BL/6). | none |
| CVCL_0139, ACH-000880 | Gastric & gastro-oesophageal junction cancer | KRAS, PIK3CA / PI3K-alpha | KRAS G12D, PIK3CA E453K, CDH1-mutant; diffuse-like. | none | |
| CVCL_0028, ACH-000940 | Endometrial cancer | FGFR2 | FGFR2 N550K, PTEN-null; the FGFR2 endometrial line. | none | |
Apc Min Apc Min/+ (germline truncation) Dozens of small-intestinal adenomas; few progress to carcinoma and few are colonic. | none | Colorectal cancer | none | Dozens of small-intestinal adenomas; few progress to carcinoma and few are colonic. | Moser et al., Science 1990 |
| CVCL_IV72 | Endometrial cancer | HER2, TP53 | Uterine serous carcinoma, HER2-amplified. | none | |
Asbestos-exposed Nf2 / Cdkn2a Intraperitoneal asbestos in Nf2+/- and Cdkn2a-deficient mice Accelerated mesothelioma with human-like genetics. | none | Mesothelioma | none | Accelerated mesothelioma with human-like genetics. | Jongsma et al., Cancer Cell 2008 |
| CVCL_0152, ACH-000222 | Pancreatic ductal adenocarcinoma, KRAS | KRAS, TROP2 | KRAS G12D, ascites-derived; TROP2- and CLDN18.2-expressing. | none | |
B16-F10 Mouse melanoma Mouse (C57BL/6) poorly immunogenic melanoma; the classic checkpoint-resistant syngeneic model. | CVCL_0159 | Melanoma, PD-1 | PD-1, CTLA-4 | Mouse (C57BL/6) poorly immunogenic melanoma; the classic checkpoint-resistant syngeneic model. | none |
Ba/F3 Mouse pro-B line made IL-3 independent by any kinase driver; the universal engine for kinase and resistance mutation panels. | CVCL_0161 | Acute myeloid leukaemia | FLT3, BCR::ABL1, ALK | Mouse pro-B line made IL-3 independent by any kinase driver; the universal engine for kinase and resistance mutation panels. | none |
Ba/F3 BCR-ABL1 mutants T315I, E255K, Y253H and myristoyl-pocket panels. | not resolved | BCR::ABL1 | BCR::ABL1 | T315I, E255K, Y253H and myristoyl-pocket panels. | none |
Ba/F3 EGFR panels Engineered exon 20 insertion, C797S and other alleles in the IL-3-dependent Ba/F3 background. | not resolved | EGFR | EGFR | Engineered exon 20 insertion, C797S and other alleles in the IL-3-dependent Ba/F3 background. | none |
Ba/F3 EML4-ALK mutants G1202R, L1196M, compound mutations; the lorlatinib and neladalkib profiling panel. | not resolved | ALK | ALK | G1202R, L1196M, compound mutations; the lorlatinib and neladalkib profiling panel. | none |
Ba/F3 ERBB2 exon 20 Engineered YVMA insertion lines for zongertinib- and sevabertinib-type TKIs. | not resolved | HER2 | HER2 | Engineered YVMA insertion lines for zongertinib- and sevabertinib-type TKIs. | none |
Ba/F3 FLT3-ITD and D835Y Engineered alleles including F691L gatekeeper. | not resolved | FLT3 | FLT3 | Engineered alleles including F691L gatekeeper. | none |
BBN carcinogen model N-butyl-N-(4-hydroxybutyl)nitrosamine in drinking water Muscle-invasive, basal-like tumours with a human-like mutational spectrum after about 20 weeks. | none | Bladder & urothelial cancer | none | Muscle-invasive, basal-like tumours with a human-like mutational spectrum after about 20 weeks. | Mouse Tumor Biology database (JAX) |
| CVCL_0153, ACH-000456 | Thyroid cancer | BRAF, TP53 | Papillary carcinoma, BRAF V600E, TP53-mutant. | none | |
Braf CA (V600E) conditional Cre-activated Braf V600E used in melanoma, lung, thyroid and colon models The shared conditional allele. | none | BRAF | none | The shared conditional allele. | Dankort et al., Nat Genet 2009 |
Braf V600E / Pten Tyr-CreERT2; Braf CA; Pten flox Tamoxifen-inducible melanoma with metastasis; the reference model for BRAF/MEK inhibition and immunotherapy combinations. | none | Melanoma | none | Tamoxifen-inducible melanoma with metastasis; the reference model for BRAF/MEK inhibition and immunotherapy combinations. | Dankort et al., Nat Genet 2009 |
Brain Tumor Resource Lab (Olson) Fred Hutch collection of paediatric brain tumour PDX lines shared free of charge. | none | Medulloblastoma | none | Fred Hutch collection of paediatric brain tumour PDX lines shared free of charge. | portal |
Brca1 / Trp53 conditional K14-Cre; Brca1 flox; Trp53 flox Basal-like tumours mirroring BRCA1 carriers; PARP-inhibitor resistance models derive from it. | none | Triple-negative breast cancer | none | Basal-like tumours mirroring BRCA1 carriers; PARP-inhibitor resistance models derive from it. | Liu et al., PNAS 2007 |
BT-474 Invasive breast carcinoma of no special type HER2-amplified, ER-positive, PIK3CA K111N; the T-DM1 and T-DXd xenograft standard. | CVCL_0179, ACH-000927 | HER2-positive breast cancer, HER2 | HER2 | HER2-amplified, ER-positive, PIK3CA K111N; the T-DM1 and T-DXd xenograft standard. | none |
BT142 Oligoastrocytoma Glioma, IDH1 R132H (hemizygous); one of few IDH-mutant glioma lines that grows. | CVCL_D718 | IDH1 / IDH2 | IDH1 / IDH2 | Glioma, IDH1 R132H (hemizygous); one of few IDH-mutant glioma lines that grows. | none |
BxPC-3 Pancreatic ductal adenocarcinoma KRAS wild-type, TP53 Y220C; the control line for KRAS studies and the Y220C reactivator line. | CVCL_0186, ACH-000535 | Pancreatic ductal adenocarcinoma, TP53, TROP2 | TP53, TROP2 | KRAS wild-type, TP53 Y220C; the control line for KRAS studies and the Y220C reactivator line. | none |
C-33 A Human papillomavirus-independent cervical squamous cell carcinoma HPV-negative cervical carcinoma with RB1 and TP53 mutations. | CVCL_1094, ACH-001333 | Cervical cancer | TP53 | HPV-negative cervical carcinoma with RB1 and TP53 mutations. | none |
| none | Triple-negative breast cancer | none | Basal-like mammary carcinoma. | Mouse Tumor Biology database (JAX) | |
| CVCL_4782 | PSMA | PSMA | PSMA-high, castration-resistant. | none | |
| CVCL_4784 | Androgen receptor | Androgen receptor | Castration-resistant LNCaP derivative, bone-metastatic. | none | |
| CVCL_0234, ACH-000433 | Renal cell carcinoma | none | VHL wild-type clear-cell line (metastasis-derived). | none | |
| CVCL_1107, ACH-000832 | Head and neck squamous cell carcinoma | EGFR, TP53 | Tongue SCC, HPV-negative, TP53 H193L. | none | |
| CVCL_0608, ACH-000511 | KRAS | KRAS | Lung, G12C. | none | |
| CVCL_0609, ACH-000392 | Non-small-cell lung cancer, TROP2 | HER2, TROP2 | HER2-amplified adenocarcinoma. | none | |
| CVCL_1115, ACH-000783 | HR-positive / HER2-negative breast cancer, Estrogen receptor | Estrogen receptor | ER-positive with CDH1 loss (lobular-like). | none | |
| CVCL_0237, ACH-000354 | Pancreatic ductal adenocarcinoma, KRAS, BRCA1 / BRCA2 | KRAS, BRCA1 / BRCA2, PARP | KRAS G12V, BRCA2 6174delT; PARP-inhibitor model. | none | |
CaSki Human papillomavirus-related cervical squamous cell carcinoma HPV16 (and HPV18 sequences) squamous line. | CVCL_1100, ACH-001336 | Cervical cancer | none | HPV16 (and HPV18 sequences) squamous line. | none |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Non-small-cell lung cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Small-cell lung cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HR-positive / HER2-negative breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HER2-positive breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Triple-negative breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Colorectal cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Pancreatic ductal adenocarcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Prostate cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Melanoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Glioma & glioblastoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Ovarian cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Gastric & gastro-oesophageal junction cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Hepatocellular carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Bladder & urothelial cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Renal cell carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Head and neck squamous cell carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Mesothelioma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Biliary tract cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Gastrointestinal stromal tumour | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Endometrial cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Cervical cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Oesophageal cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | KRAS | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | EGFR | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HER2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | BRAF | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Estrogen receptor | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | BRCA1 / BRCA2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | KIT | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | TROP2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Neuroblastoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Ewing sarcoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Osteosarcoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Medulloblastoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
| CVCL_0218, ACH-001039 | BRAF | BRAF | Colorectal, V600E. | none | |
| CVCL_2420, ACH-000278 | Ovarian cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1-mutant high-grade serous line. | none | |
| CVCL_ZJ44 | Glioma & glioblastoma | PD-1 | Mouse syngeneic glioma with stem-like features; less immunogenic than GL261. | none | |
CT26 Mouse colon adenocarcinoma Mouse (BALB/c) KRAS G12D colon line; MSS-like, moderately immunogenic. | CVCL_7254 | Colorectal cancer, KRAS, PD-1 | PD-1, KRAS | Mouse (BALB/c) KRAS G12D colon line; MSS-like, moderately immunogenic. | none |
| CVCL_1155, ACH-000055 | Medulloblastoma | none | Group 3/4-like, MYC-expressing. | none | |
D425 Med Medulloblastoma, non-WNT/non-SHH, group 3 Group 3, MYC-amplified; aggressive orthotopic model. | CVCL_1275, ACH-001053 | Medulloblastoma | none | Group 3, MYC-amplified; aggressive orthotopic model. | none |
Daoy Medulloblastoma, SHH-activated, TP53-mutant SHH-like, TP53-mutant; the most used medulloblastoma line but not group-representative. | CVCL_1167, ACH-000211 | Medulloblastoma | Smoothened, TP53 | SHH-like, TP53-mutant; the most used medulloblastoma line but not group-representative. | none |
Daudi EBV-related Burkitt lymphoma Burkitt; beta-2-microglobulin null (no HLA class I), useful for MHC-independent killing. | CVCL_0008, ACH-000786 | CD19 | CD19, CD20 | Burkitt; beta-2-microglobulin null (no HLA class I), useful for MHC-independent killing. | none |
| CVCL_1171, ACH-000207 | Head and neck squamous cell carcinoma | EGFR | Pharyngeal SCC, HPV-negative. | none | |
| CVCL_0248, ACH-001061 | Colorectal cancer | KRAS | KRAS G13D, MSI-high; used for PARP and mismatch-repair work. | none | |
| CVCL_HD56 | BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | Isogenic colorectal knock-out pair (Horizon). | none | |
DMS 114 Thoracic SMARCA4-deficient undifferentiated tumor Adherent SCLC line; SLFN11-expressing, used for TOP1 and PARP sensitivity. | CVCL_1174, ACH-000530 | Small-cell lung cancer | none | Adherent SCLC line; SLFN11-expressing, used for TOP1 and PARP sensitivity. | none |
| CVCL_0105, ACH-000979 | Prostate cancer, PSMA | PSMA | AR-negative, brain-metastasis derived. | none | |
EGFR L858R / T790M (tet-inducible) CCSP-rtTA; TetO-EGFR L858R or L858R+T790M Doxycycline-inducible mutant EGFR; tumours regress when the transgene is switched off. | none | Non-small-cell lung cancer | none | Doxycycline-inducible mutant EGFR; tumours regress when the transgene is switched off. | Politi et al., Genes Dev 2006 |
| none | EGFR | none | Inducible mutant EGFR lung tumours. | Politi et al., Genes Dev 2006 | |
| CVCL_1193, ACH-001494 | Biliary tract cancer | KRAS | Extrahepatic, KRAS G12D. | none | |
Eml4-Alk (CRISPR) In vivo Cas9-induced Eml4-Alk inversion Endogenous fusion, crizotinib-sensitive tumours. | none | Non-small-cell lung cancer | none | Endogenous fusion, crizotinib-sensitive tumours. | Maddalo et al., Nature 2014 |
| none | ALK | none | Endogenous fusion lung tumours. | Maddalo et al., Nature 2014 | |
| CVCL_1923 | PD-1 | PD-1 | Mouse breast; responsive. | none |
Check the Cellosaurus record for misidentification and contamination flags, confirm the allele you need in DepMap or Cellosaurus (G12C is not G12D), and authenticate your stock by STR profiling. Many historic lines are not what their names say.
Identifiers resolved from the Cellosaurus API on 2026-09-09; disease labels are Cellosaurus' NCIt terms. Repository links go to the portal, not to a specific model. Targets link to their dossiers.